Qdrant + Oncotelic | Building the DNA of Search | Bastian Hofmann, Saran Saund, and Scott Myers

Qdrant was engineered from the ground up for performance, scale, and flexibility — and Oncotelic Therapeutics put it to the test. Indexing 28M PubMed abstracts to power AI-driven drug development, Oncotelic compressed concept-to-clinic to ~2 years — a fraction of the typical biotech timeline. In this conversation, Qdrant Engineering and Oncotelic walk through what matters most for search at scale: hybrid retrieval, MeSH-enriched metadata filtering, and the operational realities of running a vector database in production.